Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Kazia Therapeutics

DB:NV9
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NV9
DB
A$32M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
  • Kazia Therapeutics has significant price volatility in the past 3 months.
NV9 Share Price and Events
7 Day Returns
6.5%
DB:NV9
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-16.2%
DB:NV9
-7.4%
DE Biotechs
-14.2%
DE Market
NV9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kazia Therapeutics (NV9) 6.5% -29.6% -38% -16.2% -28.8% -93.2%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • NV9 underperformed the Biotechs industry which returned -7.4% over the past year.
  • NV9 underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
NV9
Industry
5yr Volatility vs Market

NV9 Value

 Is Kazia Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Kazia Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.228.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kazia Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kazia Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NV9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-30) in AUD A$-0.16
ASX:KZA Share Price ** ASX (2020-04-06) in AUD A$0.45
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kazia Therapeutics.

DB:NV9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:KZA Share Price ÷ EPS (both in AUD)

= 0.45 ÷ -0.16

-2.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kazia Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Kazia Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Kazia Therapeutics's expected growth come at a high price?
Raw Data
DB:NV9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-13.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Kazia Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Kazia Therapeutics's assets?
Raw Data
DB:NV9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-30) in AUD A$0.17
ASX:KZA Share Price * ASX (2020-04-06) in AUD A$0.45
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:NV9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:KZA Share Price ÷ Book Value per Share (both in AUD)

= 0.45 ÷ 0.17

2.62x

* Primary Listing of Kazia Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kazia Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Kazia Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Kazia Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NV9 Future Performance

 How is Kazia Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-13.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kazia Therapeutics expected to grow at an attractive rate?
  • Unable to compare Kazia Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Kazia Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Kazia Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NV9 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NV9 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -13.8%
DB:NV9 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NV9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NV9 Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 2 -12 1
2020-06-30 2 -10 1
DB:NV9 Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-12-30 1 -5 -10
2019-09-30 1 -6 -10
2019-06-30 2 -7 -10
2019-03-31 2 -6 -11
2018-12-31 2 -5 -12
2018-09-30 3 -7 -9
2018-06-30 3 -9 -6
2018-03-31 4 -10 -6
2017-12-31 6 -12 -6
2017-09-30 7 -12 -8
2017-06-30 9 -11 -11
2017-03-31 7 -12 -12
2016-12-31 5 -12 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Kazia Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Kazia Therapeutics's revenue is expected to grow by 4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NV9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Kazia Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NV9 Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30 -0.17 -0.17 -0.17 1.00
2020-06-30 -0.14 -0.14 -0.14 1.00
DB:NV9 Past Financials Data
Date (Data in AUD Millions) EPS *
2019-12-30 -0.16
2019-09-30 -0.17
2019-06-30 -0.18
2019-03-31 -0.21
2018-12-31 -0.25
2018-09-30 -0.19
2018-06-30 -0.12
2018-03-31 -0.13
2017-12-31 -0.13
2017-09-30 -0.18
2017-06-30 -0.23
2017-03-31 -0.25
2016-12-31 -0.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Kazia Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Kazia Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kazia Therapeutics has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NV9 Past Performance

  How has Kazia Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kazia Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kazia Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Kazia Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Kazia Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Kazia Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kazia Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NV9 Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-30 1.40 -10.12 4.02 6.96
2019-09-30 1.47 -10.20 3.91 6.72
2019-06-30 1.54 -10.27 3.79 6.48
2019-03-31 1.93 -11.38 3.51 7.63
2018-12-31 2.32 -12.49 3.23 8.79
2018-09-30 2.66 -9.27 4.41 9.28
2018-06-30 3.00 -6.04 5.60 9.77
2018-03-31 4.33 -6.05 7.31 10.36
2017-12-31 5.65 -6.06 9.02 10.95
2017-09-30 7.22 -8.37 8.77 11.04
2017-06-30 8.79 -10.67 8.53 11.14
2017-03-31 6.81 -11.54 7.59 10.45
2016-12-31 4.82 -12.41 6.65 9.76
2016-09-30 4.05 -12.24 6.20 9.83
2016-06-30 3.27 -12.06 5.76 9.89
2016-03-31 3.22 -10.39 5.59 9.12
2015-12-31 3.16 -8.72 5.41 8.35
2015-09-30 2.44 -7.93 4.63 7.14
2015-06-30 1.72 -7.14 3.84 5.94
2015-03-31 1.85 -6.90 3.49 5.63
2014-12-31 1.99 -6.66 3.13 5.33
2014-09-30 1.21 -7.06 3.27 4.33
2014-06-30 0.43 -7.47 3.41 3.33
2014-03-31 0.48 -6.02 3.42 2.09
2013-12-31 0.53 -4.58 3.43 0.85
2013-09-30 0.82 -3.17 3.14 0.55
2013-06-30 1.11 -1.75 2.85 0.26

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Kazia Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Kazia Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Kazia Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Kazia Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kazia Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NV9 Health

 How is Kazia Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kazia Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kazia Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kazia Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kazia Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Kazia Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kazia Therapeutics Company Filings, last reported 3 months ago.

DB:NV9 Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-30 12.26 0.00 6.44
2019-09-30 12.26 0.00 6.44
2019-06-30 14.19 0.00 5.43
2019-03-31 14.19 0.00 5.43
2018-12-31 18.37 0.00 5.41
2018-09-30 18.37 0.00 5.41
2018-06-30 19.24 0.00 5.96
2018-03-31 19.24 0.00 5.96
2017-12-31 25.77 0.00 6.64
2017-09-30 25.77 0.00 6.64
2017-06-30 25.34 0.00 14.45
2017-03-31 25.34 0.00 14.45
2016-12-31 31.64 0.00 18.60
2016-09-30 31.64 0.00 18.60
2016-06-30 33.93 0.00 33.45
2016-03-31 33.93 0.00 33.45
2015-12-31 41.19 0.00 37.63
2015-09-30 41.19 0.00 37.63
2015-06-30 44.36 0.00 44.37
2015-03-31 44.36 0.00 44.37
2014-12-31 7.69 0.93 8.03
2014-09-30 7.69 0.93 8.03
2014-06-30 1.41 2.71 2.50
2014-03-31 1.41 2.71 2.50
2013-12-31 4.78 3.57 6.06
2013-09-30 4.78 3.57 6.06
2013-06-30 4.04 1.42 2.74
  • Kazia Therapeutics has no debt.
  • Kazia Therapeutics has no debt compared to 5 years ago when it was 12.1%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Kazia Therapeutics has sufficient cash runway for 1.3 years based on current free cash flow.
  • Kazia Therapeutics has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 2.6% each year.
X
Financial health checks
We assess Kazia Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kazia Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NV9 Dividends

 What is Kazia Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Kazia Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Kazia Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Kazia Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kazia Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NV9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NV9 Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-06-30 0.00 1.00
2020-06-30 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Kazia Therapeutics has not reported any payouts.
  • Unable to verify if Kazia Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Kazia Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Kazia Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Kazia Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Kazia Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kazia Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kazia Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NV9 Management

 What is the CEO of Kazia Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
James Garner
COMPENSATION A$691,085
AGE 46
TENURE AS CEO 4.2 years
CEO Bio

Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, has been the Chief Executive Officer, Managing Director and Executive Director of Kazia Therapeutics Limited (formerly Novogen Limited) since February 1, 2016 Dr. Garner serves as Head of the Unit Development Office, AP R&D with Sanofi and is based in Singapore. After qualifying in medicine at Imperial College in London, he spent several years as a practicing clinician in the UK and Australia before joining Bain & Company, a global management consulting company in 2002. He subsequently worked with Biogen and Progen Pharmaceuticals in Australia and with Quintiles, an international clinical research organisation in Singapore. He has broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. He served as Vice President of Medical and Clinical Affairs of Progen Pharmaceuticals Limited from January 29, 2007 to November 2008. Dr. Garner served as Medical Affairs Manager at Biogen Idec for the Asia-Pacific region. At Biogen Idec, he drove the commercial launch of a number of novel biologic therapies in nine Asian countries and also managed regional clinical research and business development activities. Since 2009, he served as Regional Vice President for Takeda Pharmaceutical Company with overall responsibility for all clinical development activities and registration of new chemical entities in the Asian region (excluding Japan), and served as General Manger. Dr. Garner served as a Corporate Strategy Consultant of Bain & Company in Sydney. He began his career practicing medicine at a number of hospitals throughout the United Kingdom and Australia. His previous responsibilities have included leading non-clinical safety and efficacy, phase I-IV clinical trials, product registration, reimbursement, medical marketing and business development. He is a Young Fellow of the Royal Society of Medicine (UK) and a member of the Australian Pharmaceutical Physicians Association. He holds a Bachelor of Sciences (with First Class Honors) from University College, London and a Master of Arts and a Master of Business Administration from the University of Queensland and a Graduate Certificate in Applied Finance and Investment from the Financial Services Institute of Australasia.

CEO Compensation
  • James's compensation has increased whilst company is loss making.
  • James's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Kazia Therapeutics management team in years:

3.6
Average Tenure
  • The tenure for the Kazia Therapeutics management team is about average.
Management Team

James Garner

TITLE
CEO, MD & Executive Director
COMPENSATION
A$691K
AGE
46
TENURE
4.2 yrs

Gabrielle Heaton

TITLE
Director of Finance & Administration
COMPENSATION
A$237K
TENURE
3.1 yrs

Kate Hill

TITLE
Company Secretary
COMPENSATION
A$162K
AGE
59
TENURE
3.6 yrs

Kym Robins

TITLE
Director of Marketing & Communications
Board of Directors Tenure

Average tenure and age of the Kazia Therapeutics board of directors in years:

3.6
Average Tenure
63
Average Age
  • The tenure for the Kazia Therapeutics board of directors is about average.
Board of Directors

Iain Ross

TITLE
Independent Chairman of the Board
COMPENSATION
A$130K
AGE
65
TENURE
2.3 yrs

James Garner

TITLE
CEO, MD & Executive Director
COMPENSATION
A$691K
AGE
46
TENURE
4.2 yrs

Steve Coffey

TITLE
Independent Non-Executive Director
COMPENSATION
A$82K
AGE
57
TENURE
7.4 yrs

Bryce Carmine

TITLE
Independent Non-Executive Director
COMPENSATION
A$82K
AGE
67
TENURE
4.8 yrs

Peter Gunning

TITLE
Member of Scientific Advisory Board
COMPENSATION
A$14K
TENURE
3.6 yrs

Murray Brennan

TITLE
Member of Scientific Advisory Board
AGE
79
TENURE
3.6 yrs

Karen Jean Ferrante

TITLE
Member of Scientific Advisory Board
AGE
61
TENURE
3.6 yrs

Alex Matter

TITLE
Member of Scientific Advisory Board
TENURE
3.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Kazia Therapeutics individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
24. Feb 20 Buy Steven Coffey Individual 20. Feb 20 20. Feb 20 10,000 €0.37 €3,739
24. Feb 20 Buy James Garner Individual 20. Feb 20 20. Feb 20 15,000 €0.39 €5,836
03. Dec 19 Buy Iain Ross Individual 26. Nov 19 26. Nov 19 125,000 €0.20 €25,470
26. Nov 19 Buy Bryce Carmine Individual 20. Nov 19 20. Nov 19 60,000 €0.20 €12,204
25. Nov 19 Sell Credit Suisse, Investment Banking and Securities Investments Company 20. Nov 19 20. Nov 19 -1,306,850 €0.28 €-361,505
25. Nov 19 Buy Credit Suisse, Investment Banking and Securities Investments Company 18. Nov 19 18. Nov 19 21,541 €0.28 €6,094
04. Sep 19 Buy James Garner Individual 28. Aug 19 03. Sep 19 10,000 €0.23 €2,322
09. Jul 19 Buy Hishenk Pty Ltd. Company 26. Jun 19 09. Jul 19 55,000 €0.23 €12,878
03. Jul 19 Sell Hishenk Pty Ltd. Company 03. Oct 18 26. Jun 19 -9,000 €0.23 €-2,099
03. Jul 19 Buy Hishenk Pty Ltd. Company 03. Oct 18 26. Jun 19 662,981 €0.28 €185,063
03. Jul 19 Buy Steven Coffey Individual 03. Jul 19 03. Jul 19 60,000 €0.21 €12,378
03. Jul 19 Buy James Garner Individual 03. Jul 19 03. Jul 19 65,000 €0.21 €13,409
03. Jul 19 Buy Bryce Carmine Individual 03. Jul 19 03. Jul 19 60,000 €0.21 €12,378
03. Jul 19 Buy Iain Ross Individual 03. Jul 19 03. Jul 19 125,000 €0.21 €25,787
X
Management checks
We assess Kazia Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kazia Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NV9 News

Simply Wall St News

NV9 Company Info

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is headquartered in Sydney, Australia.

Details
Name: Kazia Therapeutics Limited
NV9
Exchange: DB
Founded: 1994
A$18,462,710
72,416,673
Website: http://www.kaziatherapeutics.com
Address: Kazia Therapeutics Limited
Three International Towers,
Level 24,
Sydney,
New South Wales, 2000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX KZA Ordinary Shares Australian Securities Exchange AU AUD 27. Sep 1994
OTCPK NVGN.F Ordinary Shares Pink Sheets LLC US USD 27. Sep 1994
DB NV9 Ordinary Shares Deutsche Boerse AG DE EUR 27. Sep 1994
CHIA KZA Ordinary Shares Chi-X Australia AU AUD 27. Sep 1994
NasdaqCM KZIA SPONSORED ADR Nasdaq Capital Market US USD 06. Jan 1999
DB NV9M SPONSORED ADR Deutsche Boerse AG DE EUR 06. Jan 1999
Number of employees
Current staff
Staff numbers
0
Kazia Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 21:58
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/02/19
Last earnings reported: 2019/12/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.